- Home
- ZURA vs CMPS Comparison
ZURA vs CMPS Comparison
Compare ZURA & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | CMPS |
|---|---|---|
| Founded | 2022 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 1.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZURA | CMPS |
|---|---|---|
| Price | $4.46 | $15.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $13.00 | ★ $25.38 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $4.83 |
| 52 Week High | $7.25 | $15.87 |
Technical Indicators
Market Signals| Indicator | ZURA | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 60.08 |
| Support Level | $4.22 | $12.95 |
| Resistance Level | $5.94 | $15.87 |
| Average True Range (ATR) | 0.37 | 0.82 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 4.03 | 76.47 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.